Verastem, Inc. (VSTM) Receives Orphan Drug Designation in the EU for VS-6063 in Mesothelioma
6/13/2013 9:28:52 AM
More...
|
Verastem, Inc. (VSTM) Names Robert Forrester CEO
6/6/2013 7:12:56 AM
More...
|
Verastem, Inc. (VSTM) Hosts Dr. Dean Fennell for a Mesothelioma Briefing at American Society of Clinical Oncology
6/3/2013 8:00:09 AM
More...
|
Verastem, Inc. (VSTM) to Present at the 2013 American Society of Clinical Oncology Annual Meeting
5/23/2013 7:52:42 AM
More...
|
Verastem, Inc. (VSTM) to Present at Upcoming Conferences
5/21/2013 7:36:49 AM
More...
|
Jack Green Joins Verastem, Inc. (VSTM) as Chief Financial Officer
5/14/2013 7:39:04 AM
More...
|
Verastem, Inc. (VSTM) Reports First Quarter 2013 Financial and Corporate Results
5/9/2013 7:49:21 AM
More...
|
Verastem, Inc. (VSTM) to Present at Upcoming Conferences
5/8/2013 8:00:14 AM
More...
|
Verastem, Inc. (VSTM) to Present at Upcoming Conferences
4/17/2013 7:17:25 AM
More...
|
Verastem, Inc. (VSTM) to Present Scientific Results at the 2013 American Association for Cancer Research Annual Meeting
4/3/2013 6:28:43 AM
More...
|
|